全文获取类型
收费全文 | 73篇 |
免费 | 5篇 |
专业分类
基础医学 | 5篇 |
临床医学 | 8篇 |
内科学 | 44篇 |
皮肤病学 | 2篇 |
特种医学 | 3篇 |
外科学 | 8篇 |
药学 | 1篇 |
肿瘤学 | 7篇 |
出版年
2023年 | 1篇 |
2021年 | 1篇 |
2020年 | 1篇 |
2019年 | 1篇 |
2013年 | 2篇 |
2012年 | 3篇 |
2011年 | 2篇 |
2010年 | 1篇 |
2009年 | 1篇 |
2007年 | 5篇 |
2006年 | 4篇 |
2005年 | 8篇 |
2004年 | 12篇 |
2003年 | 1篇 |
2002年 | 5篇 |
2001年 | 3篇 |
2000年 | 1篇 |
1999年 | 4篇 |
1996年 | 4篇 |
1995年 | 1篇 |
1993年 | 1篇 |
1992年 | 2篇 |
1991年 | 2篇 |
1990年 | 2篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1987年 | 3篇 |
1985年 | 1篇 |
1983年 | 1篇 |
1976年 | 1篇 |
排序方式: 共有78条查询结果,搜索用时 15 毫秒
1.
2.
A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate 总被引:7,自引:0,他引:7 下载免费PDF全文
Cohen SB Moreland LW Cush JJ Greenwald MW Block S Shergy WJ Hanrahan PS Kraishi MM Patel A Sun G Bear MB; Study Group 《Annals of the rheumatic diseases》2004,63(9):1062-1068
OBJECTIVE: To assess the efficacy and safety of 100 mg daily anakinra (Kineret), a recombinant form of the naturally occurring interleukin 1 receptor antagonist, plus methotrexate (MTX) in reducing the signs and symptoms of rheumatoid arthritis (RA). METHODS: Patients with active RA (n = 506) despite current treatment with MTX were enrolled in this multicentre, double blind, randomised, placebo controlled study. Patients received subcutaneous injections of anakinra 100 mg/day or placebo. They were assessed monthly for 6 months for improvement in signs and symptoms of RA and for adverse events. The primary efficacy measure was the percentage of patients attaining ACR20 response at week 24. RESULTS: Significantly greater proportions of patients treated with anakinra compared with placebo achieved ACR20 (38% v 22%; p<0.001), ACR50 (17% v 8%; p<0.01), and ACR70 (6% v 2%; p<0.05) responses. The response to anakinra was rapid; the proportion of patients with an ACR20 response at the first study assessment (4 weeks) was twice as high with anakinra as with placebo (p<0.005). Clinically meaningful and statistically significant responses were also seen in individual components of the ACR response (for example, Health Assessment Questionnaire, pain, C reactive protein levels, and erythrocyte sedimentation rate). Anakinra was well tolerated, with a safety profile, similar to that of placebo with one exception: mild to moderate injection site reactions were more common with anakinra than with placebo (65% v 24%). CONCLUSIONS: This study confirms previous observations from a dose-ranging study showing that anakinra, in combination with MTX, is an effective and safe treatment for patients with RA who have inadequate responses to MTX alone. 相似文献
3.
Rich-Garg Neha Danve Abhijeet Choi Dongseok Vakil-Gilani Kiana Akkoc Nurullah Azevedo Valderillo Russell Anthony Sharma Aman Cush John Curtis Jeffery R. Deodhar Atul 《Clinical rheumatology》2021,40(3):949-954
Clinical Rheumatology - This study aims to assess rheumatologists’ perceptions, utilization patterns, and attitudes towards the modified New York (mNY) criteria for ankylosing spondylitis... 相似文献
4.
5.
6.
Kwock L Smith JK Castillo M Ewend MG Cush S Hensing T Varia M Morris D Bouldin TW 《Technology in cancer research & treatment》2002,1(1):17-28
Proton magnetic resonance spectroscopy (H1-MRS) has been increasingly receiving more attention from radiologists, neurosurgeons, radiation and medical oncologists in the "in situ" clinical evaluation of human tumors. The utilization of H1-MRS, especially in human brain tumors, coupled to both routine magnetic resonance imaging (MRI) and functional MRI techniques provides greater information concerning tumor grading and extension and characterization of the normal surrounding tissue than what is possible with any other imaging technique alone. In this paper, we will review the current status of proton MR spectroscopy with emphasis on its clinical utility to diagnose tumors, its utility in planning surgical and radiation therapy interventions, and in its use in monitoring tumor treatment. 相似文献
7.
8.
Rheumatic complaints are common in the geriatric population. However, uncommonly autoimmune or musculoskeletal complaints and disorders may arise as a consequence of pharmacotherapy. These rare events include statin myopathy, drug-induced lupus, arthralgias, vasculitis, or tight skin syndromes. This article will discuss the possible iatrogenic causes of rheumatic conditions, potential inciting agents, and the various types of rheumatic manifestations seen in the elderly. 相似文献
9.
Hansen's disease, leprosy, is a chronic infectious disease caused by the acid-fast bacillus Mycobacterium leprae. There are multiple forms of the disease ranging from the relatively benign to the progressive, malignant lepromatous leprosy. There is effective antimicrobial treatment available that is capable of curing the disease. We report the case of a post heart transplant patient acquiring Hansen's disease. 相似文献
10.
Adult-onset Still's disease 总被引:4,自引:0,他引:4
Cush JJ 《Bulletin on the rheumatic diseases》2000,49(6):1-4